Theravance Biopharma, Inc.
$17.12
The Read: Theravance Biopharma’s stock historically moves about 17% around partnership announcements, including the June 15 events, but has shown mixed reactions to clinical setbacks like the 26% collapse on Ampreloxetine Phase 3 failure and minor declines on earnings updates despite revenue growth.
Price
Overlays
Panel
TBPH
Hover to view data
No Data